دورية أكاديمية
أعرض في EDS

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.

التفاصيل البيبلوغرافية
العنوان: Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
المؤلفون: Chennakesavulu S; Pharmacy Department, NDDS Laboratory, Donors Plaza, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Gujarat, India., Mishra A; Pharmacy Department, NDDS Laboratory, Donors Plaza, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Gujarat, India., Sudheer A; Pharmacology Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Gujarat, India., Sowmya C; Center for Pharmaceutical Research, Pharmaceutics Department, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu 515721, Andhra Pradesh, India., Suryaprakash Reddy C; Center for Pharmaceutical Research, Pharmaceutics Department, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu 515721, Andhra Pradesh, India., Bhargav E; Center for Pharmaceutical Research, Pharmaceutics Department, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu 515721, Andhra Pradesh, India.
المصدر: Asian journal of pharmaceutical sciences [Asian J Pharm Sci] 2018 Jan; Vol. 13 (1), pp. 91-100. Date of Electronic Publication: 2017 Aug 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101535338 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2221-285X (Electronic) Linking ISSN: 18180876 NLM ISO Abbreviation: Asian J Pharm Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: [Amsterdam] : Elsevier B.V.
Original Publication: Hong Kong : Hong Kong Asiamed Pub. House
مستخلص: Dry powder inhaler Liposomes were prepared to investigate the effectiveness of pulmonary delivery of Colchicine and Budesonide for Idiopathic Pulmonary fibrosis. Budesonide (BUD) and Colchicine (COL) liposomes were prepared by thin layer film hydration method (TFH) using 1,2-Dipalmitoyl-sn-glycero-3- phosphoglycerol sodium (DPPG), Hydrogenated Soyaphosphotidylcholine (HSPC), Soyaphosphatidylcholine (SPC), cholesterol (CHOL) and drug in different weight ratios. The optimum lipid composition for BUD (74.22 ± 0.97%) was DPPG: HSPC: CHOL (4:5:1) and for COL (50.94 ± 2.04%) was DPPG: SPC: CHOL (3:6:1). These compositions retained drug for a longer period of time so selected for further study. Liposomes were found to be spherical in shape with mean size below 100 nm. Liposomes lyophilized using Mannitol as carrier and cryoprotectant showed high entrapment efficiency (97.89 - 98.6%). The powder was dispersed through an Andersen cascade impactor to evaluate the performance of the aerosolized powder. It was found that prepared liposomal dry powder inhaler (DPIs) sustained the drug release up to 24 hours. Optimized Budesonide DPI Formulation B2 (86.53 ± 1.9%), Colchicine DPI Formulation C2 (90.54 ± 2.3 %) and BUD and COL DPI Combination M2 (89.91 ± 1.8%, 91.23 ± 1.9%). Histopathological results, measurements of lung hydroxyproline content, Myeloperoxidase activity indicated that liposomal dry powder inhaler administration attenuates lung fibrosis induced by bleomycin. Long term stability studies indicated that lyophilised BUD and COL liposomes were stable for 6 months at (25 °C ± 2 °C, 60% ± 5% RH) and refrigerated conditions (2 - 8 °C). These results supported that combination of budesonide and colchicine liposomal dry powder inhaler pulmonary drug delivery for treatment of idiopathic Pulmonary Fibrosis exhibits prolonged drug retention at targeted site and reduces the systemic exposure.
Competing Interests: 5The authors thank The Principal of The Maharaja Sayajirao University of Baroda for providing required facilities to carry out the research work.
(© 2018 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V.)
References: Pak J Pharm Sci. 1995 Jul;8(2):69-79. (PMID: 16421003)
Saudi Pharm J. 2010 Oct;18(4):217-24. (PMID: 23960730)
Eur J Pharmacol. 2010 Feb 10;627(1-3):304-12. (PMID: 19909737)
J Immunol. 2011 Mar 15;186(6):3693-700. (PMID: 21307292)
Eur J Pharm Sci. 2013 Jul 16;49(4):699-711. (PMID: 23707466)
Expert Opin Drug Deliv. 2009 Jan;6(1):71-89. (PMID: 19236209)
Curr Med Chem. 2004 Feb;11(4):413-24. (PMID: 14965222)
Surg Today. 2005;35(9):744-50. (PMID: 16133669)
Cochrane Database Syst Rev. 2003;(3):CD002880. (PMID: 12917934)
Int J Biochem Cell Biol. 2008;40(3):362-82. (PMID: 17936056)
Lancet. 2011 Dec 3;378(9807):1949-61. (PMID: 21719092)
فهرسة مساهمة: Keywords: BLM, Bleomycin; Budesonide; Colchicine; DE, Drug entrapment; DPI, Dry Powder Inhaler; EPC, Egg phosphatidyl choline; FPF, Fine particle fraction; HDPE, High density polyethylene; Idiopathic Pulmonary fibrosis; Liposomal dry powder inhaler; M2, Mixture of BUD & COL (Optimized formulation); MDI's, Metered Dose Inhalers; MMAD, Mean Median Aerodynamic diameter; PBS, Saline Phosphate buffer; PVC, Poly vinyl chloride; Pulmonary drug delivery; SLS, Sodium lauryl sulphate; UV, Ultraviolet
تواريخ الأحداث: Date Created: 20200228 Latest Revision: 20200928
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7032187
DOI: 10.1016/j.ajps.2017.08.005
PMID: 32104382
قاعدة البيانات: MEDLINE
الوصف
تدمد:2221-285X
DOI:10.1016/j.ajps.2017.08.005